【白云山(00874.HK):注射用氨苄西林钠(1.0g、0.5g)已通过仿制药质量和疗效一致性评价】白云山(00874.HK)发布公告,近日,公司控股子公司广州白云山天心制药股份有限公司(以下简称“天心药业”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,注射用氨苄西林钠(1.0g、0.5g)已通过仿制药质量和疗效一致性评价。

金融界
28 Mar
白云山(00874.HK)发布公告,近日,公司控股子公司广州白云山天心制药股份有限公司(以下简称“天心药业”)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,注射用氨苄西林钠(1.0g、0.5g)已通过仿制药质量和疗效一致性评价。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10